Becton, Dickinson and Company company logo

# RNN 1st Gen Model Becton, Dickinson and Company Surgical & medical instruments

Prediction models:
Subscribe >> Deal exit on
Feb. 22, 2018
Deal entry on
Feb. 22, 2018
1.32%Expected margin
82.35% successful of 51 deals
$ 218.32 Last close price
at 22-feb-2018

BDX

Model's trade recommendations -2.57% Return for period

6.32% Annual return

$58.53B Market Cap

β 1.12  

BDX

Model (following trade recommendations)

BDX

Underlying stock

S&P 500

Index
Return for period -2.57%
-9.92%
1.78%
52wk return 8.39%
19.76%
16.82%
52wk Range
177.07—246.28
2000.54—2399.63
Sortino ratio 1.02
Sharpe ratio 0.82
Norm. RMSE 1.00%
Downside risk 5.96%
Volatility 7.38%
  • 3.00 (1.36%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Becton, Dickinson & Company is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues.

Industry sector: Medical

Sector classification: Surgical & medical instruments

Deep Learning based analysis and prediction model for Becton, Dickinson and Company (BDX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for BDX model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 264M
P/E 22.80
Shares Outstanding 266M
% Held by Insiders 1.00%
% Held by Institutions 77.50%
EPS (last reported FY) $9.48
EPS (last reported Q) $2.48
EPS, estimated (last reported Q) $2.40
Total revenues $12 B
Net income $1 B